ZBIO - Latest News
Zenas BioPharma, Inc. (ZBIO), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $889.7M. Beta to the broader market is -0.58.
The article list below shows the most recent ZBIO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ZBIO Headlines
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
globenewswire.com - May 13, 2026
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com - May 13, 2026
– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026
seekingalpha.com - Apr 30, 2026
Zenas BioPharma, Inc. maintains a Strong Buy rating, driven by obexelimab's positive phase 3 results in IgG4-RD and regulatory filings planned for 20
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - Apr 17, 2026
WALTHAM, Mass. , April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc.
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 7.6% on Insider Buying Activity
defenseworld.net - Apr 3, 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) shares rose 7.
How News Affects ZBIO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ZBIO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ZBIO news questions
- What is the latest ZBIO news headline?
- The most recent ZBIO headline (May 13, 2026) is "Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ZBIO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ZBIO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ZBIO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.